Stockpolly
Search
NRXP · NASDAQ · Biotechnology

NRx Pharmaceuticals (NRXP)

Develops NMDA-pathway CNS therapies alongside a majority-owned interventional-psychiatry clinic network.

$3.44
Pre-market−0.02 (−0.54%)
At close$3.46(+0.44%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue000000000111
Cost of revenue000000000111
Gross profit000000000000
646734444557
Research & development332311111112
224423333545
Selling & marketing000000000000
General & administrative004000330005
Other expenses000000000000
Operating income−6−4−6−7−3−4−4−4−4−5−5−7
00−1−11−5−2−14−253−10
Interest income000000000000
Interest expense000100000100
Other non-operating income0000−152142−6−410
Income before tax−6−4−7−8−2−9−6−18−60−1−17
Net income from continuing operations−6−4−7−8−2−9−6−18−60−1−17
Net income−6−4−7−8−2−9−6−18−60−1−17
EPS, basic−$0.74−$0.05−$0.74−$0.75−$0.15−$0.86−$0.34−$0.98−$0.27$0.01−$0.04−$0.44
EPS, diluted−$0.74−$0.05−$0.74−$0.75−$0.15−$0.86−$0.34−$0.98−$0.27$0.01−$0.04−$0.44
Weighted average shares, basic8849111111161822323238
Weighted average shares, diluted8849111111161822323238
EBITDA−6−4−6−7−2−9−6−18−61−1−16
Depreciation & amortization000000000000
EBIT−6−4−6−7−2−9−6−18−61−1−16